Adverse drug reactions

Min Kyung Cho, Dong Yoon Kang, Hye Ryun Kang

Research output: Contribution to journalArticle

1 Scopus citations


There are no drugs without the risk of potential adverse reactions. All pharmacologically active substances can cause adverse drug reactions (ADRs). This paper aims at introducing recent trends in pharmacosurveillance systems for ADRs, which can be broadly classified into type A and B reactions. Since type A reactions are associated with drug pharmacology, they are usually dose-dependent and predictable. Whereas, type B reactions occur in some susceptible individuals, regardless of the pharmacological action of drug. Drug hypersensitivity reactions are typical examples of type B reactions and are subclassified according to the underlying pathomechanism. Recent advancements in pharmacogenomics have enlightened the understanding of individual differences in drug efficacy and susceptibility to ADRs. Therefore, expectations for safe personalized medicines are higher than ever before. However, premarketing clinical trials are too small and too short to uncover rare but serious ADRs and detect long-standing ADRs. In the past, post-marketing surveillance systems mainly focused on passive ADR monitoring systems, based on spontaneous reports. Recently, the importance of active pharmacovigilance systems, which use big data, is growing with recent advancements in medical informatics. Thus, regarding ADRs, suspecting and detecting the causative drug using causality assessment based on data science may contribute to decrease suffering induced by ADRs.

Original languageEnglish
Pages (from-to)472-479
Number of pages8
JournalJournal of the Korean Medical Association
Issue number9
StatePublished - 1 Jan 2019


  • Adverse drug reaction reporting systems
  • Big data
  • Drug-related side effects and adverse reactions
  • Pharmacogenetics
  • Pharmacovigilance

Fingerprint Dive into the research topics of 'Adverse drug reactions'. Together they form a unique fingerprint.

  • Cite this